Private equity firm Abris Capital Partners is reportedly considering the sale of Scanmed, a prominent healthcare company based in Poland, according to undisclosed sources familiar with the matter. The potential divestment comes amid Abris’s ongoing strategy to evaluate its investment portfolio and seize favorable market conditions.
Scanmed, a key player in the Polish healthcare sector, offers a wide range of medical services, including diagnostic imaging, laboratory diagnostics, and telemedicine solutions. With a network comprising numerous modern clinics and medical centers across the country, the company has established itself as a trusted provider of comprehensive healthcare services.
Abris Capital Partners, a renowned private equity firm focused on Central and Eastern Europe, acquired Scanmed in 2017. Since then, the firm has worked closely with the management team to enhance the company’s operations and expand its service offerings. Now, Abris is exploring the possibility of relinquishing its stake in Scanmed to capitalize on the strong investor interest in the healthcare industry.
The deliberations regarding the sale of Scanmed come at an opportune time, as the healthcare sector continues to attract substantial investment attention. The COVID-19 pandemic has underscored the importance of robust healthcare infrastructure and services, leading to increased demand and investment opportunities within the industry. By evaluating the potential divestment, Abris aims to leverage this favorable market landscape and unlock significant value from its investment in Scanmed.
While details about the potential sale remain confidential, industry insiders suggest that Abris could initiate discussions with prospective buyers in the coming months. The private equity firm is expected to engage in negotiations with interested parties, evaluating their alignment with Scanmed’s strategic vision and commitment to delivering high-quality healthcare services.
For Abris Capital Partners, divesting its stake in Scanmed would mark another significant move in optimizing its investment portfolio. The firm has a track record of successfully identifying lucrative opportunities and strategically exiting investments to generate attractive returns for its investors. By assessing the potential sale of Scanmed, Abris continues to demonstrate its agility and expertise in navigating the ever-evolving landscape of private equity investments.
In conclusion, Abris Capital Partners is reportedly contemplating the sale of Scanmed, a leading healthcare company in Poland. The firm’s evaluation of this divestment opportunity aligns with its broader strategy of assessing investment portfolios and capitalizing on favorable market conditions. As the healthcare sector garners significant investor interest, Abris seeks to leverage this momentum by exploring potential buyers for Scanmed. Through this potential sale, Abris aims to optimize its investment portfolio, generate attractive returns, and further solidify its position as a prominent player in Central and Eastern Europe’s private equity landscape.
